Could six months of bupropion double quit rates for african american smokers?

NCT ID NCT05732272

Recruiting now Disease control Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether taking the quit-smoking drug bupropion for 6 months works better than the usual 7-week course for African American adults who smoke daily. Researchers will enroll 500 participants and check if more people stay smoke-free at 6 months with the longer treatment. The goal is to find a more effective way to help this community quit smoking for good.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bupropion
What this could lead to: If successful, this could provide a more effective, tailored smoking cessation approach for African American smokers, who often face higher quit barriers.
What could go wrong: This is a Phase 3 trial, but results may not apply to all smokers. Bupropion can cause side effects like insomnia or dry mouth, and some participants may still relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMOKING CESSATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMOKING CESSATION

Contacts and locations

Locations

University of Kansas Medical Center
RECRUITING

Kansas City, Missouri, 64130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.